Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO
-
Published:2020-10-07
Issue:1
Volume:124
Page:183-190
-
ISSN:0007-0920
-
Container-title:British Journal of Cancer
-
language:en
-
Short-container-title:Br J Cancer
Author:
Rossini Daniele, Lonardi Sara, Antoniotti Carlotta, Santini Daniele, Tomasello Gianluca, Ermacora Paola, Germani Marco Maria, Bergamo Francesca, Ricci Vincenzo, Caponnetto Salvatore, Moretto Roberto, Zaniboni Alberto, Pietrantonio Filippo, Buonadonna Angela, Ritorto Giuliana, Masi Gianluca, Latiano Tiziana Pia, Rapisardi Stefania, Falcone Alfredo, Cremolini ChiaraORCID
Abstract
Abstract
Background
FOLFOXIRI/bevacizumab (bev) is a first-line regimen of proven activity and efficacy in metastatic colorectal cancer. The upfront exposure to three cytotoxics raises concerns about the efficacy of treatments after progression.
Methods
We performed a pooled analysis of treatments after progression to upfront FOLFOXIRI/bev in patients enrolled in two randomised Phase 3 studies (TRIBE and TRIBE2) that compared FOLFOXIRI/bev to doublets (FOLFOX or FOLFIRI)/bev. Response rate, progression-free survival (2nd PFS) and overall survival (2nd OS) during treatments after progression were assessed. The RECIST response in first line and the oxaliplatin and irinotecan-free interval (OIFI) were investigated as potential predictors of benefit from FOLFOXIRI ± bev reintroduction.
Results
Longer 2nd PFS was reported in patients receiving FOLFOXIRI ± bev reintroduction compared to doublets ± bev or other treatments (6.1 versus 4.4 and 3.9 months, respectively, P = 0.013), and seems limited to patients achieving a response during first line (6.9 versus 4.2 and 4.7 months, respectively, P = 0.005) and an OIFI ≥ 4 months (7.2 versus 6.5 and 4.6 months, respectively, P = 0.045).
Conclusions
First-line FOLFOXIRI/bev does not impair the administration of effective second-line therapies. First-line response and longer OIFI seem associated with improved response and 2nd PFS from FOLFOXIRI ± bev reintroduction, without impacting 2nd OS.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Reference24 articles.
1. Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 27, 1386–1422 (2016). 2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colon cancer, version 3. https://www.https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf (accessed May 23, 2020) (2020). 3. Loupakis, F., Cremolini, C., Masi, G., Lonardi, S., Zagonel, V., Salvatore, L. et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N. Engl. J. Med. 371, 1609–1618 (2014). 4. Gruenberger, T., Bridgewater, J., Chau, I., García Alfonso, P., Rivoire, M., Mudan, S. et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann. Oncol. 26, 702–708 (2015). 5. Schmoll, H., Garlipp, B., Junghanß, C., Vogel, A., Kaiser, U., Florschütz, A. et al. FOLFOX/bevacizumab +/− irinotecan in advanced colorectal cancer (CHARTA): long term outcome. Ann. Oncol. 29, Suppl. 5, v108 (2018).
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|